FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200385015> ?p ?o ?g. }

• W4200385015 endingPage "156" @default.
• W4200385015 startingPage "155" @default.
• W4200385015 abstract "Vasopressors are the cornerstone of hemodynamic management in patients with septic shock. Norepinephrine is currently recommended as the first-line vasopressor in these patients. In addition to norepinephrine, there are many other potent vasopressors with specific properties and/or advantages that act on vessels through different pathways after activation of specific receptors; these could be of interest in patients with septic shock. Dopamine is no longer recommended in patients with septic shock because its use is associated with a higher rate of cardiac arrhythmias without any benefit in terms of mortality or organ dysfunction. Epinephrine is currently considered as a second-line vasopressor therapy, because of the higher rate of associated metabolic and cardiac adverse effects compared with norepinephrine; however, it may be considered in settings where norepinephrine is unavailable or in patients with refractory septic shock and myocardial dysfunction. Owing to its potential effects on mortality and renal function and its norepinephrine-sparing effect, vasopressin is recommended as second-line vasopressor therapy instead of norepinephrine dose escalation in patients with septic shock and persistent arterial hypotension. However, two synthetic analogs of vasopressin, namely, terlipressin and selepressin, have not yet been employed in the management of patients with septic shock, as their use is associated with a higher rate of digital ischemia. Finally, angiotensin Ⅱ also appears to be a promising vasopressor in patients with septic shock, especially in the most severe cases and/or in patients with acute kidney injury requiring renal replacement therapy. Nevertheless, due to limited evidence and concerns regarding safety (which remains unclear because of potential adverse effects related to its marked vasopressor activity), angiotensin Ⅱ is currently not recommended in patients with septic shock. Further studies are needed to better define the role of these vasopressors in the management of these patients." @default.
• W4200385015 created "2021-12-31" @default.
• W4200385015 creator A5067470337 @default.
• W4200385015 creator A5083028574 @default.
• W4200385015 date "2022-04-01" @default.
• W4200385015 modified "2023-10-18" @default.
• W4200385015 title "Adherence to surviving sepsis campaign guidelines 2016 regarding fluid resuscitation and vasopressors in the initial management of septic shock: The emerging part of the iceberg!" @default.
• W4200385015 cites W1969829944 @default.
• W4200385015 cites W2054938569 @default.
• W4200385015 cites W2102820915 @default.
• W4200385015 cites W2122560363 @default.
• W4200385015 cites W2127138854 @default.
• W4200385015 cites W2163814324 @default.
• W4200385015 cites W2214145300 @default.
• W4200385015 cites W2560080100 @default.
• W4200385015 cites W2614741637 @default.
• W4200385015 cites W2801360758 @default.
• W4200385015 cites W2802319261 @default.
• W4200385015 cites W2806162392 @default.
• W4200385015 cites W2891441581 @default.
• W4200385015 cites W2892366363 @default.
• W4200385015 cites W2898967013 @default.
• W4200385015 cites W2901237139 @default.
• W4200385015 cites W2944740795 @default.
• W4200385015 cites W2979776779 @default.
• W4200385015 cites W3008040894 @default.
• W4200385015 cites W3016555942 @default.
• W4200385015 cites W3017100980 @default.
• W4200385015 cites W3023757607 @default.
• W4200385015 cites W3202964273 @default.
• W4200385015 cites W771907615 @default.
• W4200385015 doi "https://doi.org/10.1016/j.jcrc.2021.11.015" @default.
• W4200385015 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34895776" @default.
• W4200385015 hasPublicationYear "2022" @default.
• W4200385015 type Work @default.
• W4200385015 citedByCount "3" @default.
• W4200385015 countsByYear W42003850152022 @default.
• W4200385015 crossrefType "journal-article" @default.
• W4200385015 hasAuthorship W4200385015A5067470337 @default.
• W4200385015 hasAuthorship W4200385015A5083028574 @default.
• W4200385015 hasConcept C126322002 @default.
• W4200385015 hasConcept C164705383 @default.
• W4200385015 hasConcept C177713679 @default.
• W4200385015 hasConcept C2776370428 @default.
• W4200385015 hasConcept C2776988256 @default.
• W4200385015 hasConcept C2777628635 @default.
• W4200385015 hasConcept C2778165595 @default.
• W4200385015 hasConcept C2778384902 @default.
• W4200385015 hasConcept C2778426790 @default.
• W4200385015 hasConcept C2778514916 @default.
• W4200385015 hasConcept C2779393834 @default.
• W4200385015 hasConcept C2779541074 @default.
• W4200385015 hasConcept C2780472472 @default.
• W4200385015 hasConcept C2780496750 @default.
• W4200385015 hasConcept C2781300812 @default.
• W4200385015 hasConcept C42219234 @default.
• W4200385015 hasConcept C513476851 @default.
• W4200385015 hasConcept C71924100 @default.
• W4200385015 hasConceptScore W4200385015C126322002 @default.
• W4200385015 hasConceptScore W4200385015C164705383 @default.
• W4200385015 hasConceptScore W4200385015C177713679 @default.
• W4200385015 hasConceptScore W4200385015C2776370428 @default.
• W4200385015 hasConceptScore W4200385015C2776988256 @default.
• W4200385015 hasConceptScore W4200385015C2777628635 @default.
• W4200385015 hasConceptScore W4200385015C2778165595 @default.
• W4200385015 hasConceptScore W4200385015C2778384902 @default.
• W4200385015 hasConceptScore W4200385015C2778426790 @default.
• W4200385015 hasConceptScore W4200385015C2778514916 @default.
• W4200385015 hasConceptScore W4200385015C2779393834 @default.
• W4200385015 hasConceptScore W4200385015C2779541074 @default.
• W4200385015 hasConceptScore W4200385015C2780472472 @default.
• W4200385015 hasConceptScore W4200385015C2780496750 @default.
• W4200385015 hasConceptScore W4200385015C2781300812 @default.
• W4200385015 hasConceptScore W4200385015C42219234 @default.
• W4200385015 hasConceptScore W4200385015C513476851 @default.
• W4200385015 hasConceptScore W4200385015C71924100 @default.
• W4200385015 hasLocation W42003850151 @default.
• W4200385015 hasLocation W42003850152 @default.
• W4200385015 hasOpenAccess W4200385015 @default.
• W4200385015 hasPrimaryLocation W42003850151 @default.
• W4200385015 hasRelatedWork W1504831884 @default.
• W4200385015 hasRelatedWork W197399609 @default.
• W4200385015 hasRelatedWork W2008804728 @default.
• W4200385015 hasRelatedWork W2022768974 @default.
• W4200385015 hasRelatedWork W2228877416 @default.
• W4200385015 hasRelatedWork W2383724224 @default.
• W4200385015 hasRelatedWork W2610490428 @default.
• W4200385015 hasRelatedWork W2920939747 @default.
• W4200385015 hasRelatedWork W2994793273 @default.
• W4200385015 hasRelatedWork W4282600974 @default.
• W4200385015 hasVolume "68" @default.
• W4200385015 isParatext "false" @default.
• W4200385015 isRetracted "false" @default.
• W4200385015 workType "article" @default.